Study of Vosaroxin With Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome With Excess Blasts-2

NCT03338348 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndrome With Excess Blasts-2 (MDS-EB-2)

Interventions

DRUG: Vosaroxin
DRUG: Azacitidine

Sponsor

University of Ulm

Collaborators

[object Object]